Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)
ID: 357288Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research projects focused on implementing Screening, Brief Intervention, and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use among adult populations experiencing health disparities. The initiative aims to develop innovative strategies to enhance the effectiveness of SBIRT/P, particularly targeting disadvantaged groups such as racial and ethnic minorities, rural communities, and individuals with disabilities. This funding is part of a broader effort to address health inequities related to substance use disorders and requires strong partnerships with healthcare and community organizations. Interested applicants must adhere to NIH application guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP), and submit their proposals by May 7, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-26-001.html.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health, is issuing a Notice of Funding Opportunity (NOFO) to support research projects implementing Screening, Brief Intervention, and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use among adult populations experiencing health disparities. This funding, part of the cardiovascular health initiative, aims to innovative strategies to enhance SBIRT/P's effectiveness, particularly in disadvantaged groups such as racial and ethnic minorities, rural communities, and individuals with disabilities. Eligible applicants may include various institutions and organizations focusing on health disparities. Funded projects must demonstrate strong partnerships with healthcare and community organizations, integrating preventive measures against ATOD misuse. Funding is contingent upon availability and the quality of submissions, and applicants must adhere strictly to NIH application guidelines, including a required Plan for Enhancing Diverse Perspectives (PEDP). The program emphasizes tackling barriers to effective treatment referrals and expanding clinical trial engagement. The NOFO reflects a growing recognition of the need for culturally and contextually relevant interventions to effectively address health inequities related to substance use disorders.
    Similar Opportunities
    Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at improving Screening, Brief Intervention, and Referral to Treatment or Prevention (SBIRT/P) strategies for alcohol, tobacco, and other drug (ATOD) use among adult populations experiencing health disparities. This initiative seeks innovative approaches to implement SBIRT/P, focusing on addressing the unique barriers faced by these populations, and encourages collaboration with healthcare and community partners to enhance the sustainability of these interventions. The funding opportunity, categorized as R01, is part of NIH's broader goal to increase prevention research targeting leading risk factors for morbidity and mortality, with applications due starting January 5, 2024, and closing on May 7, 2027. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders" (R34 Clinical Trial Optional). This initiative encourages pilot studies aimed at preparing for larger-scale effectiveness trials that focus on optimizing access, quality, and affordability of substance use disorder treatments and related services, with an emphasis on diverse perspectives through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $450,000 in direct costs for a three-year grant, with application due dates beginning January 16, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-100.html.
    Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R34 - Clinical Trial Optional)." This initiative aims to support pilot and preliminary research that prepares for larger-scale trials focused on improving access to and the effectiveness of treatment services for substance use disorders. The funding is intended to facilitate the testing of various intervention approaches and methodologies, ultimately contributing to the development of effective treatment strategies that address health disparities among vulnerable populations. Applicants may receive up to $450,000 over a three-year period, with proposals due by 5:00 PM local time on January 7, 2025. For further information, interested parties can contact the NIH OER Webmaster at grantsinfo@nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PA-21-180.html.
    Alcohol Health Services Research (R34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Alcohol Abuse and Alcoholism (NIAAA), has announced a funding opportunity titled "Alcohol Health Services Research (R34 Clinical Trial Optional)" (PAR-23-252). This initiative aims to address the treatment gap for individuals with Alcohol Use Disorder (AUD) by focusing on improving access to treatment, reducing stigma, examining cost structures, and implementing evidence-based approaches, particularly for health disparity populations. The total project budget is capped at $450,000 over a three-year period, and eligible applicants include higher education institutions, nonprofits, and government agencies, with a specific emphasis on those serving underrepresented communities. Interested parties should submit their applications electronically by October 16, 2023, with funding available until September 8, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional)" aimed at supporting policy research projects that investigate the impact of tobacco, alcohol, and cannabis policies on health disparities in the U.S. The initiative seeks exploratory research that engages community organizations to promote equity in cancer prevention by addressing substance use and exposure among disadvantaged populations. This grant program, with an estimated total funding of $200,000 and an award ceiling of $200,000, emphasizes the importance of community partnerships and diverse research team perspectives. Applications are due by January 7, 2028, and interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-241.html.
    Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at promoting research for innovative behavioral and integrative treatments for drug and alcohol use disorders. This initiative encourages the development and testing of interventions across various stages, from initial generation and refinement to efficacy testing in controlled and real-world settings, focusing on enhancing treatment efficacy and accessibility, particularly in community environments. Applications are welcomed from a diverse range of organizations, including higher education institutions and for-profit entities, with no budget limit specified, and must be submitted by March 21, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-182.html.
    Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Phased Research to Support Substance Use Epidemiology, Prevention, and Services Studies (R61/R33 Clinical Trials Optional)," aimed at advancing translational research in the field of substance use. This initiative encourages researchers to engage in a two-phase research process, starting with an R61 planning phase lasting up to two years, followed by an R33 phase for larger studies that may extend up to four years, contingent upon meeting specific milestones. The program emphasizes the importance of community stakeholder engagement and mandates a Plan for Enhancing Diverse Perspectives (PEDP) in all proposals to ensure inclusivity in research development. Interested applicants can find more information and submit their proposals by December 14, 2026, and should direct inquiries to grantsinfo@nih.gov.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R01 Basic Experimental Studies with Humans Required)," aimed at advancing research on non-invasive brain stimulation (NIBS) as a treatment for substance use disorders (SUDs). This initiative encourages innovative proposals that explore novel NIBS targets and neurobiological responses, with a focus on understanding the mechanisms underlying SUDs through clinical trials involving human subjects. The NIH plans to allocate $1.5 million annually over three years to fund approximately six grants, with applications due by January 16, 2024. Interested applicants can find more information and guidance on the required Plan for Enhancing Diverse Perspectives (PEDP) at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled the Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) aimed at advancing research in behavioral and integrative treatments for substance use and dependence. This program encourages the development and testing of innovative behavioral therapies through a structured approach that includes intervention generation, efficacy testing in research settings, and real-world efficacy assessments, with a focus on diverse populations and the use of technology. The funding amount is contingent on NIH appropriations, with a maximum project period of five years, and applications are due by February 5, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-299.html.
    Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at small business concerns (SBCs) to develop technologies that address health-related social needs impacting substance use disorders (SUD), excluding alcohol use disorder. This initiative, titled "Seeking Products to Address Social Needs impacting SUD," invites applications for Small Business Technology Transfer (STTR) grants under phases I and II, with a total funding amount of $1.3 million available for four awards in FY 2025. The focus is on leveraging innovative technologies, such as telemedicine and mobile health applications, to improve conditions like housing instability and food insecurity that influence SUD outcomes. Interested applicants must comply with specific eligibility criteria and application guidelines, with a submission deadline of March 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-047.html.